Get the Stockscreener App
3.51
2.37%
-0.08
Curevac N V stock is traded at $3.51, with a volume of 272.37K.
It is down -2.37% in the last 24 hours and up +17.62% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$3.59
Open:
$3.54
24h Volume:
272.37K
Relative Volume:
0.44
Market Cap:
$765.53M
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
6.4004
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-1.54%
1M Performance:
+17.62%
6M Performance:
+23.42%
1Y Performance:
+17.62%
1-Day Range:
$3.48
$3.585
1-Week Range:
$3.26
$3.64
52-Week Range:
$2.37
$5.28
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
3.51 | 765.53M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.75 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.08 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
550.39 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.06 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.02 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
Analysts Offer Valuable Insight On CureVac N.V (CVAC) - Stocksregister
CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy? - Defense World
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - ACCESS Newswire
Geode Capital Management LLC Acquires 22,491 Shares of CureVac (NASDAQ:CVAC) - Defense World
UBS Group Lowers CureVac (NASDAQ:CVAC) Price Target to $12.00 - Defense World
CVAC (CureVac N.V) has impressive results - uspostnews.com
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth - simplywall.st
Legal & General Group Plc Has $359,000 Holdings in CureVac (NASDAQ:CVAC) - Defense World
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
CureVac (CVAC) Target Price Reduced by UBS Analyst | CVAC Stock News - GuruFocus
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating - marketscreener.com
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet - ACCESS Newswire
CureVac N.V (CVAC) Stock: Navigating a Year of Stock Volatility - investchronicle.com
CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s Why - Defense World
Can you still get a good price for CureVac N.V (CVAC) Shares at this point? - uspostnews.com
CureVac (CVAC) to Release Quarterly Earnings on Wednesday - Defense World
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
CureVac: 2025 will be less costly - marketscreener.com
CureVac Announces Financial Results for the Fourth Quarter and F - GuruFocus
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - Yahoo Finance
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience By GuruFocus - Investing.com Canada
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus
CureVac Reports Strong 2024 Financial Results and Strategic Progress - TipRanks
CureVac Reports 2024 Financial Results and Strategic Advances - TipRanks
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - ACCESS Newswire
CureVac Q4 2024 Earnings Call Transcript - MarketBeat
Insights Ahead: CureVac's Quarterly Earnings - Benzinga
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
FDA clears CureVac’s IND application for Phase I lung cancer trial - MSN
FDA clears Curevac’s IND for CVHNLC - BioWorld MedTech
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - sharewise.com
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - ACCESS Newswire
CureVac Financial Results: Key mRNA Biotech Player to Reveal 2024 Performance - Stock Titan
CureVac’s lung cancer therapy clears FDA hurdle - Investing.com Australia
CureVac’s lung cancer therapy clears FDA hurdle By Investing.com - Investing.com South Africa
CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance - MarketScreener
CureVac to initiate Phase 1 trial for its lung cancer therapy (CVAC:NASDAQ) - Seeking Alpha
CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy - MarketScreener
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - sharewise.com
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - ACCESS Newswire
CureVac's Revolutionary mRNA Cancer Treatment Gets FDA Green Light for Lung Cancer Trial - Stock Titan
CureVac N.V.'s (NASDAQ:CVAC) Profit Outlook - simplywall.st
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):